TABLE 2.
Antihypertensive Medication Reductions and Objective Tumor Responses Among 68 Patients with Advanced PPGL Who Received at Least 1 Dose of HSA 131I-MIBG
| Parameter | One therapeutic dose (n = 18) | Two therapeutic doses (n = 50) | At least 1 therapeutic dose (n = 68) |
| Reduction of all antihypertensive medications by ≥50% for ≥6 mo (n) | |||
| Yes | 1 (6%) (95% CI, 0–28) | 16 (32%) (95% CI, 21–46) | 17 (25%) (95% CI, 16–37) |
| No | 17 (94%) | 34 (68%) | 51 (75%) |
| Best confirmed overall tumor response by RECIST 1.0 (n) | |||
| Evaluated patients | 14 | 50 | 64 |
| CR | 0 | 0 | 0 |
| PR | 0 | 15 (30%) | 15 (23%) |
| Stable disease | 10 (71%) | 34 (68%) | 44 (69%) |
| Progressive disease | 2 (14%) | 1 (2%) | 3 (5%) |
| No assessment | 2 (14%) | 0 | 2 (3%) |